Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
about
Guidelines for the management of soft tissue sarcomasAdvanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinA Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue SarcomaPazopanib in the management of advanced soft tissue sarcomasThe value of trabectedin in the treatment of soft tissue sarcomaPrinciples in Management of Soft Tissue SarcomaEfficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewCurrent and future options in the management and treatment of uterine sarcomaPractice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus StatementAdvances in sarcoma diagnostics and treatmentUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTEribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalMolecular Targets and Emerging Therapeutic Options for Uterine LeiomyosarcomaCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasUK guidelines for the management of soft tissue sarcomasOsteosarcoma in Korean children and adolescentsManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinTreatment of Adult Soft Tissue Sarcomas: An OverviewPazopanib in the treatment of soft tissue sarcomaFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.The evolution of systemic therapy in sarcoma.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignanciesA Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Operative and Conservative Treatment of Uterine SarcomasRadiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas.Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysisRole of expert centres in the management of sarcomasClinical management of secondary angiosarcoma after breast conservation therapyResponse of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature reviewSystemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and EribulinPulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).
P2860
Q21296866-C989470B-4C3C-4287-A6C1-781D2E094854Q26738346-B83457ED-C678-4357-A6F0-313CFEC81C08Q26741817-6D32CC06-0F7B-4D3D-BCB6-586749C7DAFBQ26746205-771FFCEE-DB03-4827-9C19-46181BA67FCEQ26772855-6C5273A0-C546-4227-9654-378F05463342Q26795619-2779D4C5-EAB6-48B1-9A09-42000E2F52D3Q26822530-983B75E9-181C-487E-A1C5-C0B5F66CEBB7Q27013559-94A670EE-94D3-4970-A262-55B0B595456EQ28069514-1BDD9855-0598-4E83-91F1-4C98C772E182Q28069695-CEC3571B-3E86-4FF8-BCBB-9BA74057428EQ28073290-6B1F79A2-5D27-4E99-B76A-817055B16BC8Q28074125-FFC00774-D2F6-4401-86CC-001BEA84DDB1Q28076023-80925A37-09B1-4E9D-A4F0-F3E04D39B2EEQ28076210-FC4C77A9-4C2A-425F-8EED-AF56599D3BA9Q28076730-7F4A9F37-C2BD-4E17-BFB3-A52E0955909BQ28083794-E68869D6-DCB1-4B45-8094-3483D92589CFQ28087771-BADB4085-149B-4342-ADD3-228FBFC274DEQ28088685-0D71FE2C-5F1A-417B-A05C-9D97CC3C66F1Q28269229-AFAECC50-E0E2-493B-AE08-500ED95BB8D6Q30439459-433C4E44-340B-4FB1-8EE7-146AEE779764Q33274710-F71049CB-0DB7-496D-95BE-AEF88424CE19Q33379886-50F40F41-E4AD-4C4C-AFE1-001A32838EE6Q33397403-0CEDA5DA-641A-414C-AD9D-83119157CE82Q33400419-525E5E5D-ADE6-4E14-B48A-95A28EC8C6BEQ33400959-D563C6AA-26A4-4853-B8D3-9FEE1F97630BQ33403798-600FF733-2B0C-48E6-9528-8072E466F949Q33419792-8666BB4F-F063-4FC8-AC8B-E2D79F429C82Q33423203-2ACB9F98-F1B4-4742-AC68-F10A14A176B4Q33427160-262BCC77-A61B-4F6C-A145-747747B5087CQ33438485-14CB1E34-9DB5-4747-BE26-CBD3828470B1Q33439510-E737E94C-B6B9-4AC9-8FE5-1DFA12545938Q33626132-E66B8667-5ECB-4160-9114-442F62744C41Q33641267-205CBC53-7881-4ED0-BC1C-7890784333FFQ33657779-33C36C7C-C7AF-44D6-A3B3-4BEABE7FEB98Q33697957-4F8DC136-13ED-4C9C-84CA-D43829B89A82Q33751719-582BD47F-E8A9-4004-A164-462DFE3EB826Q33872963-67C65BBC-2FF7-4E84-BD3F-8FC7E183C026Q33890846-2E4AADE3-1FCE-4C39-AA64-7BD4BE396B52Q33891037-658FC10B-A0E0-436B-8EF2-312092B39251Q34045393-B0E55863-26EC-4159-9A06-A95F884D0A8A
P2860
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Randomized phase II study of g ...... oration study 002 [corrected].
@ast
Randomized phase II study of g ...... oration study 002 [corrected].
@en
Randomized phase II study of g ...... oration study 002 [corrected].
@nl
type
label
Randomized phase II study of g ...... oration study 002 [corrected].
@ast
Randomized phase II study of g ...... oration study 002 [corrected].
@en
Randomized phase II study of g ...... oration study 002 [corrected].
@nl
prefLabel
Randomized phase II study of g ...... oration study 002 [corrected].
@ast
Randomized phase II study of g ...... oration study 002 [corrected].
@en
Randomized phase II study of g ...... oration study 002 [corrected].
@nl
P2093
P356
P1476
Randomized phase II study of g ...... oration study 002 [corrected].
@en
P2093
Brian Samuels
David C Harmon
Denise Reinke
Dennis A Priebat
J Kyle Wathen
Laurence H Baker
Martee L Hensley
Michael Fanucchi
Peter F Thall
Robert S Benjamin
P304
P356
10.1200/JCO.2006.10.4117
P407
P577
2007-07-01T00:00:00Z